News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
372,185 Results
Type
Article (24557)
Company Profile (34)
Press Release (347594)
Multimedia
Podcasts (79)
Webinars (7)
Section
Business (121913)
Career Advice (1453)
Deals (17712)
Drug Delivery (65)
Drug Development (43634)
Employer Resources (99)
FDA (8892)
Job Trends (8664)
News (194678)
Policy (17568)
Tag
Academia (1487)
Academic (1)
Accelerated approval (4)
Adcomms (11)
Allergies (49)
Alliances (33703)
ALS (55)
Alzheimer's disease (827)
Antibody-drug conjugate (ADC) (87)
Approvals (8922)
Artificial intelligence (171)
Autoimmune disease (13)
Automation (13)
Bankruptcy (160)
Best Places to Work (7191)
BIOSECURE Act (12)
Biosimilars (50)
Biotechnology (27)
Bladder cancer (61)
Brain cancer (15)
Breast cancer (192)
Cancer (1528)
Cardiovascular disease (115)
Career advice (1235)
Career pathing (24)
CAR-T (80)
Cell therapy (276)
Cervical cancer (15)
Clinical research (35466)
Collaboration (635)
Compensation (121)
Complete response letters (12)
COVID-19 (1518)
CRISPR (27)
C-suite (124)
Cystic fibrosis (57)
Data (1499)
Decentralized trials (2)
Denatured (24)
Depression (23)
Diabetes (188)
Diagnostics (3434)
Digital health (10)
Diversity (3)
Diversity, equity & inclusion (29)
Drug discovery (75)
Drug pricing (66)
Drug shortages (19)
Duchenne muscular dystrophy (65)
Earnings (55562)
Editorial (31)
Employer branding (14)
Employer resources (86)
Events (55223)
Executive appointments (419)
FDA (9657)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (1)
Frontotemporal dementia (4)
Funding (415)
Gene editing (62)
Generative AI (19)
Gene therapy (213)
GLP-1 (439)
Government (2394)
Grass and pollen (4)
Guidances (50)
Healthcare (10334)
Huntington's disease (12)
IgA nephropathy (18)
Immunology and inflammation (76)
Indications (22)
Infectious disease (1594)
Inflammatory bowel disease (91)
Inflation Reduction Act (9)
Influenza (27)
Intellectual property (65)
Interviews (268)
IPO (8440)
IRA (32)
Job creations (1829)
Job search strategy (1025)
Kidney cancer (7)
Labor market (22)
Layoffs (245)
Leadership (17)
Legal (4499)
Liver cancer (39)
Lung cancer (238)
Lymphoma (98)
Machine learning (3)
Management (34)
Manufacturing (195)
MASH (49)
Medical device (6692)
Medtech (6696)
Mergers & acquisitions (9637)
Metabolic disorders (450)
Multiple sclerosis (55)
NASH (9)
Neurodegenerative disease (53)
Neuropsychiatric disorders (15)
Neuroscience (1146)
NextGen: Class of 2025 (3476)
Non-profit (2708)
Now hiring (5)
Obesity (224)
Opinion (168)
Ovarian cancer (43)
Pain (52)
Pancreatic cancer (49)
Parkinson's disease (83)
Partnered (12)
Patents (145)
Patient recruitment (61)
Peanut (23)
People (28894)
Pharmaceutical (10)
Pharmacy benefit managers (9)
Phase I (10616)
Phase II (15149)
Phase III (12713)
Pipeline (947)
Policy (100)
Postmarket research (1690)
Preclinical (4612)
Press Release (31)
Prostate cancer (92)
Psychedelics (18)
Radiopharmaceuticals (154)
Rare diseases (237)
Real estate (2632)
Recruiting (38)
Regulatory (11914)
Reports (21)
Research institute (1356)
Resumes & cover letters (221)
Rett syndrome (2)
RNA editing (3)
RSV (28)
Schizophrenia (42)
Series A (73)
Series B (42)
Service/supplier (3)
Sickle cell disease (36)
Special edition (9)
Spinal muscular atrophy (70)
Sponsored (17)
Startups (1599)
State (1)
Stomach cancer (13)
Supply chain (35)
Tariffs (27)
The Weekly (53)
Vaccines (456)
Venture capitalists (20)
Weight loss (140)
Women's health (18)
Worklife (14)
Date
Today (95)
Last 7 days (516)
Last 30 days (1594)
Last 365 days (19752)
2025 (6651)
2024 (20671)
2023 (22753)
2022 (29304)
2021 (31033)
2020 (30170)
2019 (25778)
2018 (19048)
2017 (18060)
2016 (17472)
2015 (19906)
2014 (16595)
2013 (14521)
2012 (14385)
2011 (13849)
2010 (13074)
Location
Africa (562)
Alabama (40)
Alaska (5)
Arizona (86)
Arkansas (7)
Asia (21648)
Australia (3650)
California (3465)
Canada (1194)
China (317)
Colorado (174)
Connecticut (184)
Delaware (92)
Europe (51433)
Florida (615)
Georgia (136)
Idaho (20)
Illinois (294)
India (19)
Indiana (200)
Iowa (3)
Japan (115)
Kansas (56)
Kentucky (8)
Louisiana (4)
Maine (27)
Maryland (494)
Massachusetts (2691)
Michigan (123)
Minnesota (178)
Missouri (32)
Montana (8)
Nebraska (9)
Nevada (35)
New Hampshire (30)
New Jersey (1180)
New Mexico (12)
New York (1062)
North Carolina (609)
North Dakota (4)
Northern California (1524)
Ohio (105)
Oklahoma (11)
Oregon (20)
Pennsylvania (825)
Puerto Rico (1)
Rhode Island (21)
South America (770)
South Carolina (14)
Southern California (1325)
Tennessee (66)
Texas (512)
United States (13610)
Utah (120)
Virginia (76)
Washington D.C. (44)
Washington State (331)
West Virginia (2)
Wisconsin (30)
372,185 Results for "merck sharp and dohme".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cancer
Merck’s Injectable Keytruda Matches IV Formula in Pivotal Trial
Merck’s new formulation of the mega-blockbuster Keytruda, made in collaboration with Alteogen, could help to keep the drug’s patent cliff at bay.
March 28, 2025
·
2 min read
·
Dan Samorodnitsky
Vaccines
Sales of Merck’s 4-Way Measles Vaccine Take Hit as US Dips Into Stockpile
Proquad is rarely a newsmaker from Merck’s earnings, but this time around, the U.S. has had a series of measles outbreaks. Sales of the vaccine were $539 million for the quarter, a 5% decline from the same period in 2024.
April 24, 2025
·
2 min read
·
Annalee Armstrong
Cardiovascular disease
Merck’s Winrevair Cuts Morbidity, Mortality Risk by Over 75% in Phase III PAH Study
Merck continues to build the case for the pulmonary arterial hypertension drug that won FDA approval in 2024.
April 1, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Merck KGaA Moves Ahead on SpringWorks Buy for $3.9B
The transaction is expected to close in the second half of 2025. With the deal, Merck KGaA is adding to its rare disease and oncology pipelines.
April 28, 2025
·
3 min read
·
Tristan Manalac
Collaboration
Merck Eyes Oral Peptide Delivery With Cyprumed Deal Worth up to $493M
Merck has not disclosed which of its peptide therapies it plans to develop oral formulations for.
April 15, 2025
·
2 min read
·
Tristan Manalac
Earnings
Tariff Uncertainty Reigns Over Q1 Earnings, With Merck Taking $200M Blow So Far
Merck, Bristol Myers Squibb, Sanofi and Roche had little clarity on the potential impact of President Donald Trump’s pharmaceutical tariffs but many companies are already preparing for what’s to come.
April 24, 2025
·
3 min read
·
Annalee Armstrong
Cancer
Arcus Challenges Merck in Kidney Cancer with Early Data
Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, according to analysts at Truist Securities.
February 18, 2025
·
2 min read
·
Tristan Manalac
Press Releases
STX PARTNERS LLP and Newlin Investment Co. Exercise Warrants of Sharp Therapeutics Corp.
April 21, 2025
·
3 min read
Collaboration
Merck Commits Nearly $2B for Oral Lipid-Lowering Drug from Chinese Biotech
Merck joins a growing list of companies targeting lipoprotein(a), high levels of which are associated with an elevated risk of adverse cardiovascular outcomes.
March 25, 2025
·
2 min read
·
Tristan Manalac
FDA
2024 Ends With Greenlights for Merck’s PAH Drug in UK and BMS’ Opdivo Injection in US
Regulators squeezed in two final approvals before the calendar change with the UK approval of Merck’s Winrevair and the FDA’s greenlight for an injectable formulation of BMS’s cancer blockbuster.
January 2, 2025
·
2 min read
·
Kate Goodwin
1 of 37,219
Next
